Kinaxo contributes quantitative phosphoproteomics platform to find a
drug to treat pancreatic cancer
27 February 2009
German company Kinaxo Biotechnologies GmbH has announced that it has
been awarded a grant by the Bavarian Research Foundation (Bayerische
Forschungsstiftung) to expand applications for its quantitative
phosphoproteomics platform to contribute to a drug efficacy study to
find a treatment for pancreatic cancer.
Quantitative phosphoproteomics enables analysis of the
phosphoproteome, which includes all phosphorylation events occurring in
a specific cell line or tissue. Since the majority of targeted small
molecules used as anticancer drugs influence the cell’s signal
transduction pathways, quantification of phosphorylation patterns in
relation to drug administration delivers insights into a compound’s
cellular mode of action.
Moreover, non-responsiveness to a multitude of compounds is a
fundamental problem in cancer treatment. Quantitative phosphoproteomics
is a powerful method to unveil the mechanisms of both cellular
resistance and a drug’s effect. It can also be a valuable tool to
discover predictive biomarkers that foretell the therapeutic outcome in
a patient which in turn allows a targeted therapy approach.
To develop new methods for individualized tumour therapy in
pancreatic cancer, Kinaxo Biotechnologies GmbH has now joined an
interdisciplinary collaboration with Priaxon AG, Genomatix Software
GmbH, the Technical University Munich and the University Hospital “Rechts
der Isar” to perform a large-scale drug efficiency study.
Despite the fact that several small molecules show significant
promise for the treatment of pancreatic cancer, so far no considerable
breakthroughs have been achieved.
Pancreatic cancer shows a mortality rate of 95%, with crucial
tumour-relevant processes being very poorly understood and only a
vanishing number of patients responding to standard therapies.
Therefore, the aim of the collaboration is to establish tools for
identifying tumour-relevant signal transduction pathways and therapeutic
Kinaxo will use its quantitative phosphoproteomics approach to
evaluate the efficacy of established and new compounds for pancreatic
cancer treatment and to try to identify predictive biomarkers that
facilitate the design and monitoring of individualized therapeutic
Bookmark this page